Literature DB >> 24188028

Minimum active structure of insulin-like peptide 5.

Alessia Belgi1, Ross A D Bathgate, Martina Kocan, Nitin Patil, Suode Zhang, Geoffrey W Tregear, John D Wade, Mohammed Akhter Hossain.   

Abstract

Insulin-like peptide 5 (INSL5) is a complex two-chain peptide hormone constrained by three disulfide bonds in a pattern identical to insulin. High expression of INSL5 in the colon suggests roles in activation of colon motility and appetite control. A more recent study indicates it may have significant roles in the regulation of insulin secretion and β-cell homeostasis. This peptide thus has considerable potential for the treatment of eating disorders, obesity, and/or diabetes. However, the synthesis of INSL5 is extremely challenging either by chemical or recombinant means. The A-chain is very poorly soluble and the B-chain is highly aggregating in nature which, together, makes their postsynthesis handling and purification very difficult. Given these difficulties, we have developed a highly active INSL5 analogue that has a much simpler structure with two disulfide bonds and is thus easier to assemble compared to native INSL5. This minimized peptide represents an attractive new mimetic for investigating the functional role of INSL5.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24188028     DOI: 10.1021/jm400924p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  General lack of structural characterization of chemically synthesized long peptides.

Authors:  Jean A Boutin; André L Tartar; Alain van Dorsselaer; Hubert Vaudry
Journal:  Protein Sci       Date:  2019-03-25       Impact factor: 6.725

Review 2.  Relaxin family peptides: structure-activity relationship studies.

Authors:  Nitin A Patil; K Johan Rosengren; Frances Separovic; John D Wade; Ross A D Bathgate; Mohammed Akhter Hossain
Journal:  Br J Pharmacol       Date:  2017-01-19       Impact factor: 8.739

3.  Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor.

Authors:  Sheng Y Ang; Dana S Hutchinson; Nitin Patil; Bronwyn A Evans; Ross A D Bathgate; Michelle L Halls; Mohammed A Hossain; Roger J Summers; Martina Kocan
Journal:  Br J Pharmacol       Date:  2016-07-13       Impact factor: 8.739

4.  The actions of relaxin family peptides on signal transduction pathways activated by the relaxin family peptide receptor RXFP4.

Authors:  Sheng Y Ang; Dana S Hutchinson; Bronwyn A Evans; Mohammed A Hossain; Nitin Patil; Ross A D Bathgate; Martina Kocan; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-26       Impact factor: 3.000

5.  A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function.

Authors:  Ruslan V Pustovit; Xiaozhou Zhang; Jamie Jm Liew; Praveen Praveen; Mengjie Liu; Ada Koo; Lalita Oparija-Rogenmozere; Qinghao Ou; Martina Kocan; Shuai Nie; Ross Ad Bathgate; John B Furness; Mohammed Akhter Hossain
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-30

Review 6.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Mechanism for insulin-like peptide 5 distinguishing the homologous relaxin family peptide receptor 3 and 4.

Authors:  Meng-Jun Hu; Xiao-Xia Shao; Jia-Hui Wang; Dian Wei; Yu-Qi Guo; Ya-Li Liu; Zeng-Guang Xu; Zhan-Yun Guo
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

8.  Real-time examination of cAMP activity at relaxin family peptide receptors using a BRET-based biosensor.

Authors:  Adam L Valkovic; Miranda B Leckey; Alice R Whitehead; Mohammed A Hossain; Asuka Inoue; Martina Kocan; Ross A D Bathgate
Journal:  Pharmacol Res Perspect       Date:  2018-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.